Cell-cycle Arrest and Senescence in TP53-wild Type Renal Carcinoma by Enhancer RNA-P53-bound Enhancer Regions 2 (p53BER2) in a P53-dependent Pathway
Overview
General Medicine
Authors
Affiliations
TP53 is a classic tumor suppressor, but its role in kidney cancer remains unclear. In our study, we tried to explain the role of p53 in kidney cancer through the p53-related enhancer RNA pathway. Functional experiments were used to explore whether P53-bound enhancer regions 2 (p53BER2) has a role in the cell cycle and senescence response of TP53-wild type (WT) renal cancer cells in vitro or vivo. RNA-sequencing was used to identify the potential target of p53BER2. The results showed that the expression level of P53BER2 was downregulated in renal cancer tissues and cell lines, further dual-luciferase experiments and APR-256-reactivated experiments showed p53BER2 expresses in a p53-dependent way. Moreover, knockdown p53BER2 could reverse nutlin-3-induced cytotoxic effect in TP53-WT cell lines. Further exploration showed the downregulation of p53BER2 could reverse nutlin-3-induced G1-arrest and senescence in TP53-WT cell lines. What is more, the knockdown of p53BER2 showed resistance to nutlin-3 treatment in vivo. Additionally, we found BRCA2 could be regulated by p53BER2 in vitro and vivo; further experiment showed p53BER2 could induce cell-cycle arrest and DNA repair by mediating BRCA2. In summary, the p53-associated enhancer RNA-p53BER2 mediates the cell cycle and senescence of p53 in TP53-WT renal cancer cells.
Role of epigenetics in paediatric cancer pathogenesis & drug resistance.
Leung J, Chiu H, Taneja R Br J Cancer. 2025; .
PMID: 40055485 DOI: 10.1038/s41416-025-02961-2.
Samarasekera G, Go N, Choutka C, Xu J, Takemon Y, Chan J PLoS Biol. 2025; 23(3):e3003034.
PMID: 39982959 PMC: 11882052. DOI: 10.1371/journal.pbio.3003034.
Bu S, Ling J, Wu X, Zhang L, Shi X, Huang L Front Endocrinol (Lausanne). 2025; 15():1509445.
PMID: 39845889 PMC: 11750652. DOI: 10.3389/fendo.2024.1509445.
Goman A, Ize B, Jeannot K, Pin C, Payros D, Goursat C J Extracell Vesicles. 2025; 14(1):e270032.
PMID: 39840902 PMC: 11752146. DOI: 10.1002/jev2.70032.
Resistance mechanisms to immune checkpoint inhibitors: updated insights.
Alsaafeen B, Ali B, Elkord E Mol Cancer. 2025; 24(1):20.
PMID: 39815294 PMC: 11734352. DOI: 10.1186/s12943-024-02212-7.